Breakthrough in Prader-Willi Treatment

This chapter explores the approval of Vicat XR, the first dedicated drug for Prader-Willi syndrome, discussing its implications for patients and the challenges overcome during its development. It also examines the broader context of rare genetic diseases and the evolving landscape of genetics in biotechnology.

Transcript

Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!

Get the app